The investment, which is in response to an increased market for spray drying and capsule filling for dry powder inhalers, will provide the contract development and manufacturing organisation (CDMO) with greater capacity to handle larger quantities of pharmaceutical powders and commercial volumes of finished dosage forms.
The expanded facility will see the GMP production area triple in size and will be home to some of the world’s leading spray drying and capsule filling technologies, to be operational by Q4 2017.
Micro-Sphere Founder and President of the Board, Dr Michele Müller, said: "Both GMP spray drying as a particle engineering technique and low dose capsule filling are becoming increasingly popular across the market and at present there are very few CDMOs offering this level of capability, especially with our level of niche expertise.
"From our expanded facility, we will continue to produce both clinical and commercial products, with a particular specialism in dry powder inhalers.
"We look forward to unveiling the technologies we will be adding to our facility in the coming months and what I can promise is it will be some of the finest equipment in the world."